Wegovy Drive Lifts Novo Nordisk's 2026 Guidance
TL;DR Summary
Novo Nordisk raised its 2026 guidance after a strong Q1 powered by Wegovy, with U.S. Wegovy prescriptions around 1.3 million and Wegovy sales of 2.26 billion DKK; first-quarter sales rose 32% cc to 96.8 billion DKK and reported operating profit jumped 65%, though adjusted sales fell 4% and adjusted profit fell 6% excluding a $4.2 billion 340B-related adjustment. The company plans to launch Wegovy outside the U.S. in H2 2026, and the stock rose intraday but closed at a new five-year low amid competition in the GLP-1 weight-loss market.
- Wegovy pill sales smash forecasts, sending Novo Nordisk stock 7% higher CNBC
- Novo Nordisk says US peptide craze boosting Wegovy weight-loss pill sales Financial Times
- Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly Reuters
- Novo Says New Obesity Pill Success Will Limit Sales Decline Bloomberg.com
- Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock? Zacks Investment Research
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
5 min
vs 6 min read
Condensed
91%
1,005 → 89 words
Want the full story? Read the original article
Read on CNBC